A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis
Phase 2
Recruiting
- Conditions
- Onychomycosis
- Interventions
- Drug: ATB1651-102- Cohort 1Drug: ATB1651-102- Cohort 2Drug: ATB1651-102- Cohort 3Drug: ATB1651-102- Cohort 4Drug: Placebo
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- AmtixBio Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06327295
- Locations
- 🇳🇿
New Zealand Clinical Research Christchurch, Christchurch, New Zealand
A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis
Phase 1
Completed
- Conditions
- Onychomycosis
- Interventions
- Drug: ATB1651, 2 mg/mLDrug: ATB1651, 5 mg/mLDrug: ATB1651, 10 mg/mLDrug: ATB1651, 20 mg/mLDrug: ATB1651, 30 mg/mLOther: Placebo
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- AmtixBio Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05089409
- Locations
- 🇳🇿
New Zealand Clinical Research Christchurch, Christchurch, New Zealand
© Copyright 2025. All Rights Reserved by MedPath